SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation (TSE: 4543) today announced a series of strategic leadership appointments to further strengthen its global operations and drive continued innovation in medical technology. The changes, effective October 1, 2024, included key positions within the Cardiac and Vascular Company and Terumo Americas Holding, Inc.
New Leadership Appointments
Fumihisa Hirose was promoted to Group Managing Executive Officer and President of the Cardiac and Vascular Company. Mr. Hirose previously served as President of the Cardiac and Vascular Company and Division President of the Interventional Systems Division.
Ghada Farah was appointed as Division President of the Interventional Systems Division within the Cardiac and Vascular Company. Ms. Farah brought extensive experience to this role, having previously served as Senior Vice President for EMEA in the Interventional Systems Division at Terumo Europe N.V.
James Rushworth was named President and Chief Operating Officer (COO) of Terumo Medical Corp. Mr. Rushworth's previous role was Chief Commercial Officer (CCO) for the Interventional Systems Division within the Cardiac and Vascular Company and President and CEO of Terumo Medical Corp.
Katsuyuki Honda was appointed President and CEO of Terumo Americas Holding, Inc., and Chairman and CEO of Terumo Medical Corp. Mr. Honda previously held the position of Regional Representative for the Americas and President and CEO of Terumo Americas Holding, Inc., and Chairman and CEO of Terumo Medical Corp.
Yasuhiro Ikoma was named Chief Commercial Officer (CCO) for the Interventional Systems Division within the Cardiac and Vascular Company. Mr. Ikoma previously served as Vice President of Global Marketing for the Interventional Systems Division in the Cardiac and Vascular Company.
Additional Leadership Transition
Effective November 1, 2024, Itaru Sakaguchi transitioned from his role as President of the Medical Care Solutions Company to the position of Division President within the Hospital Care Solutions Division of the Medical Care Solutions Company.
About Terumo
Terumo Corporation (TSE: 4543) is a leading global medical technology company committed to "Contributing to Society through Healthcare." Headquartered in Tokyo, Japan, Terumo's global presence spans more than 160 countries and regions, with over 30,000 associates dedicated to providing innovative medical solutions.
Terumo's comprehensive portfolio includes:
Vascular intervention and cardio-surgical solutions
Blood transfusion and cell therapy technology
Medical products for daily clinical practice, such as transfusion systems, diabetes care, and peritoneal dialysis treatments
Terumo is dedicated to improving patient care and enhancing quality of life through innovative and high-quality medical technologies.